MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Bonothyrk Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Bonothyrk (Parathyroid Cytomax A-21) is a Khavinson-class parathyroid peptide bioregulator: a calf-parathyroid peptide extract standardized to about 10 mg of active peptides per capsule. Rather than replacing parathyroid hormone, it is proposed to act as a tissue-specific epigenetic signal, with short peptides entering cell nuclei to modulate parathyroid- and bone-related gene expression (Molecules 2021, PMC8619776; Biochemistry [Moscow] 2011, DOI 10.1134/S0006297911110022). The manufacturer's standard course is 1-2 capsules once or twice daily with meals, most commonly about 20 mg/day for 30 days, repeated every 3-6 months. It is taken orally (a sublingual version also exists); the subcutaneous reconstitution math on this page is an educational measurement reference only. The evidence is dominated by the developer's own group and is mostly class-level animal data; there are no independent randomized human trials, and Bonothyrk is not FDA- or EMA-approved. Educational content only, not medical advice.
Reconstitute: Add 1 mL bacteriostatic water → 20 mg/mL concentration.
Typical dose: 20 mg/day oral (2 × 10 mg capsules); 30-day course, repeated every 3-6 months
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.
Storage: Commercial capsules: store at room temperature 15-25 °C, dry, away from direct light and moisture. For the educational subcutaneous model: lyophilized powder stored frozen at −20 °C; reconstituted solution refrigerated at 2-8 °C and used within about 4 weeks.
Half-life: No formal PK published; short di-/tri-/tetrapeptides are hydrolyzed within minutes and oral bioavailability is low. Proposed durable effect attributed to epigenetic gene-expression changes, the rationale for 30-day courses every 3-6 months.
Route: Oral 10 mg capsules taken with meals (a sublingual 'lingual' version also exists). Modeled here as a subcutaneous reconstitution reference for measurement only, not a recommended injection route.
Status: Not FDA- or EMA-approved; sold as a dietary supplement in Russia and a research/educational supplement elsewhere. No independent RCTs. Educational content, not medical advice.
About Bonothyrk
Bonothyrk (also sold as Parathyroid Cytomax A-21) is an orally administered parathyroid peptide bioregulator from the Khavinson family of short-peptide "Cytomax" tissue extracts. Clinically it is swallowed as 10 mg capsules with meals, so the Bonothyrk dosage is expressed in capsules rather than injected micrograms; the subcutaneous reconstitution figures below are an educational measurement reference only, not the real-world route [1][2].\n\nThe manufacturer's standard course is 1-2 capsules, one to two times daily with food, most often two 10 mg capsules per day (about 20 mg/day) for 30 days, repeated every 3-6 months [1]. To translate that onto this site's reconstitution convention, a 20 mg vial mixed with 1.0 mL of bacteriostatic water yields 20 mg/mL (200 mcg per insulin-syringe unit), so one 10 mg capsule-equivalent measures 50 units (0.5 mL) on a U-100 syringe and a 20 mg daily total measures 100 units. Many users in the manufacturer protocol begin with a single 10 mg dose to assess tolerance, then move to the twice-daily 30-day course [1].\n\nFrequency: In the educational subcutaneous model, inject twice daily to mirror the two-capsules-per-day oral schedule; the real product is taken by mouth, and a sublingual "lingual" version also exists. Bonothyrk is not FDA- or EMA-approved and is presented here for educational purposes only, not as medical advice.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 1.0 mL of bacteriostatic water into a sterile syringe (this yields a 20 mg/mL solution from a 20 mg vial).
Inject the water slowly down the inner wall of the vial; do not aim the stream directly at the powder, and avoid vigorous shaking.
Gently swirl or roll the vial until the solution is completely clear; the result is 20 mg/mL, or 200 mcg per insulin-syringe unit.
Store refrigerated at 2-8 °C and draw 50 units (0.5 mL) for one 10 mg capsule-equivalent dose, or 100 units (1.0 mL) split across two injections for a 20 mg daily total.
Educational note: Bonothyrk is clinically taken ORALLY as 10 mg capsules with meals (a sublingual version also exists); these subcutaneous reconstitution figures are a measurement reference only and are not a recommended route for an oral supplement product.
Interactive Bonothyrk Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 1 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 1mL water yields 20.00 mg/mL. To evaluate a 250mcg dose, pull to 1.3 units (1 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Days 1-3 — gentle introduction (one 10 mg capsule-equivalent once daily) | 10000 mcg (10 mg) | 50 units (0.50 mL) |
| Days 4-30 — standard 30-day course, twice daily (~20 mg/day total) | 10000 mcg (10 mg) | 50 units (0.50 mL) |
| Severe cases (clinician-guided) — twice daily, higher frequency (~40 mg/day) | 10000 mcg (10 mg) | 50 units (0.50 mL) |
| Maintenance — repeat the 30-day course every 3-6 months | 10000 mcg (10 mg) | 50 units (0.50 mL) |
Administration guidelines: Refer to guidelines | 1 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Bonothyrk, 20 mg each):
- checkOne 20 mg/day course-equivalent uses ~1 vial/day; a 30-day course ≈ 30 vials (600 mg)
- check8 weeks continuous at 20 mg/day ≈ 56 vials; 12 weeks ≈ 84 vials; 16 weeks ≈ 112 vials
- checkReal-world use is short 30-day oral courses repeated every 3-6 months, so scale vial counts to the number of courses rather than continuous weeks
Insulin Syringes (U-100):
- checkTwice-daily dosing: 14 syringes per week
- check8 weeks ≈ 112 syringes; 12 weeks ≈ 168 syringes; 16 weeks ≈ 224 syringes
- checkEach 10 mg dose draws 50 units (0.5 mL) at 20 mg/mL; a 20 mg day is two 50-unit injections
Bacteriostatic Water (30 mL bottles): Use 1 mL per 20 mg vial for reconstitution.
- check8 weeks (20 mg/day) ≈ 56 mL ≈ 2 bottles
- check12 weeks (20 mg/day) ≈ 84 mL ≈ 3 bottles
- check16 weeks (20 mg/day) ≈ 112 mL ≈ 4 bottles
Alcohol Swabs:
- checkAbout 2 swabs per injection (vial top + site), with two injections per day ≈ 4/day
- check8 weeks ≈ 224 swabs; 12 weeks ≈ 336 swabs
- check16 weeks ≈ 448 swabs; keep extras for re-swabbing multi-use vials
Mechanism of Action (MOA)
Bonothyrk belongs to the "Cytomax" branch of Khavinson peptide bioregulators: complexes of low-molecular-weight peptides (di-, tri- and tetrapeptides plus larger fractions) isolated from the parathyroid glands of young cattle and standardized to roughly 10 mg of active peptides per capsule [1][4]. It is important to distinguish this from parathyroid hormone (PTH) replacement. Bonothyrk does not supply PTH (1-84) or teriparatide-style PTH fragments; instead its proposed mechanism is epigenetic and tissue-specific [2].\n\nThe central hypothesis of the Khavinson school is that very short peptides are small enough to cross the cell membrane and nuclear envelope without a dedicated receptor, enter the nucleus and nucleolus, and bind specific promoter sequences and histone proteins to up- or down-regulate transcription of tissue-relevant genes. Fluorescence-microscopy work by Fedoreyeva and colleagues directly demonstrated that fluorescein-labeled short peptides (for example epitalon and pinealon) accumulate in the cytoplasm, nucleus and nucleolus of human (HeLa) cells and interact in vitro with deoxyribooligonucleotides and double-stranded DNA [3]. A 2021 systematic review in Molecules summarized evidence that peptides of 2-7 residues can modulate gene expression, DNA methylation status and protein synthesis across multiple cell types [2]. Applied to parathyroid tissue, Bonothyrk is claimed to normalize parathyroid-cell function and, indirectly, calcium-phosphate handling and bone remodeling.\n\nThat physiological target matters because the parathyroid glands are the master regulator of serum calcium: PTH raises ionized calcium by stimulating osteoclastic bone resorption (through osteoblast RANKL/osteoprotegerin signaling), increasing renal distal-tubule calcium reabsorption, lowering phosphate reabsorption, and inducing renal 1-alpha-hydroxylase to activate vitamin D and boost intestinal calcium absorption [5][6]. Bonothyrk is marketed for conditions framed around this axis — osteoporosis risk, demineralization, and hypocalcemia-related muscle cramps and weakness — on the premise that restoring parathyroid-cell signaling supports calcium balance and bone mineral density.\n\nPharmacokinetics are poorly characterized, which is an honest gap in the evidence. Short peptides of this type are rapidly hydrolyzed by plasma and tissue peptidases, giving a circulating half-life on the order of minutes, and the oral bioavailability of intact peptide is expected to be low. No formal absorption, distribution or half-life data specific to Bonothyrk have been published. The Khavinson rationale for a 30-day course repeated only every 3-6 months is precisely that the proposed benefit is a durable epigenetic shift in gene expression rather than a sustained plasma drug level [1][7].\n\nFinally, the strength of evidence should be read carefully: most efficacy and longevity data come from the developer's own group, largely in rodents and in Russian-language publications, and report effects of bioregulators as a class (for example 20-40% increases in rodent lifespan) rather than placebo-controlled human trials of Bonothyrk specifically [1][4][7]. The real route is oral; the subcutaneous scheme here is a measurement convention only.
Clinical Trial Efficacy Highlights
- starThe mechanistic premise has direct experimental support: Fedoreyeva and colleagues (Biochemistry [Moscow], 2011) showed that fluorescein-labeled short Khavinson peptides penetrate into the cytoplasm, nucleus and nucleolus of human HeLa cells and bind deoxyribooligonucleotides and double-stranded DNA in vitro, supporting the idea that peptide bioregulators can physically reach and interact with chromatin [3].
- starA systematic review by Khavinson and colleagues (Molecules, 2021) collated evidence that peptides of 2-7 amino acids regulate gene expression, histone interactions and DNA methylation across plants, rodents, primates and human cells, which is the proposed basis for tissue-specific bioregulators such as Bonothyrk, though the review is largely authored by the developer's group [2].
- starAcross roughly four decades of work summarized by Khavinson and Anisimov (Bull Exp Biol Med, 2009; Biogerontology, 2010), long-term treatment with peptide bioregulators as a class increased mean lifespan in rodents by approximately 20-40% and slowed several biomarkers of aging; these are class-level animal data, not Bonothyrk-specific human outcomes [1][4].
- starExperimental geroprotection has been reported for the peptide-bioregulator class (Khavinson, Kuznik and Ryzhak, Advances in Gerontology, 2013), including suppression of spontaneous and chemically or radiation-induced tumorigenesis in animal models, again at the class level rather than for the parathyroid preparation specifically [7].
- starThe physiological rationale is well established independently of the product: the parathyroid glands maintain serum calcium through PTH-driven bone resorption, renal calcium reabsorption and vitamin-D activation (StatPearls parathyroid physiology), so a bioregulator that genuinely normalized parathyroid-cell function would plausibly influence calcium balance and bone turnover [5][6].
- starManufacturer and developer-group materials describe bone-density and calcium-metabolism benefits, for example an often-cited observation of improved bone-mineral-density parameters after a 30-day course in peri-menopausal women at high osteoporosis risk, but these reports are not indexed, peer-reviewed, placebo-controlled trials and have not been independently replicated, so they should be treated as preliminary [1].
- starOverall, there are no independent randomized controlled trials of Bonothyrk in humans; the evidence base is dominated by the developer's institute, concentrates on the bioregulator class rather than the parathyroid complex, and does not establish efficacy for osteoporosis or any disease by conventional clinical-trial standards [2][4].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningManufacturer materials describe Bonothyrk as generally well tolerated with no characterized serious adverse-event profile, but this reflects the absence of rigorous controlled safety trials rather than proof of safety; long-term human safety is not established.
- warningTheoretical calcium-balance risk: because the target axis governs serum calcium, people with parathyroid disease, hyperparathyroidism, hyper- or hypocalcemia, or calcium kidney stones (urolithiasis) should not self-treat without endocrinology oversight, since miscorrected calcium can cause arrhythmia, cramps, or stone formation [5][6].
- warningAs a bovine tissue-derived extract, allergic or hypersensitivity reactions are possible, and theoretical concerns about animal-sourced biological material (immunogenicity and contaminant risk) cannot be fully excluded.
- warningRoute caution: the real product is an oral capsule taken with meals, where mild gastrointestinal upset is the most plausible everyday complaint. The subcutaneous reconstitution model on this page is educational only; injecting a product manufactured as an oral supplement would carry infection, abscess and contamination risks and is not advised.
- warningDrug-interaction data are lacking: concurrent use with calcium or vitamin D supplements, bisphosphonates, or PTH analogs (teriparatide/abaloparatide) has not been studied, and combining agents that affect calcium handling could compound effects unpredictably.
- warningNot recommended in pregnancy, breastfeeding, or children given the absence of safety data; the manufacturer restricts use to ages 14 and above.
- warningRegulatory and research status: Bonothyrk is not FDA- or EMA-approved for any indication. It is sold as a dietary supplement in Russia and as a research or educational supplement elsewhere, so peptide identity, manufacturing quality, and dose accuracy are not guaranteed to pharmaceutical standards.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Bonothyrk dosage?expand_more
In the manufacturer protocol the typical Bonothyrk dosage is 1-2 capsules (each about 10 mg of active parathyroid peptides) taken one to two times daily with meals, most commonly two 10 mg capsules per day for a total of about 20 mg/day. The standard course runs 30 days and is repeated every 3-6 months; in severe cases the developer's guidance allows up to 2 capsules twice daily (~40 mg/day). It is taken orally; the subcutaneous figures on this page (10 mg ≈ 50 units at 20 mg/mL) are an educational measurement reference only, not a recommended injection protocol.
Is Bonothyrk FDA approved?expand_more
No. Bonothyrk is not approved by the FDA or the EMA for any indication. It originates from the St. Petersburg Institute of Bioregulation and Gerontology and is registered and sold as a dietary supplement (parapharmaceutical) in Russia; in the United States and elsewhere it is sold only as a research or educational supplement. There are no independent randomized controlled trials demonstrating efficacy, and this page is educational content, not medical advice.
What is the half-life of Bonothyrk?expand_more
No formal pharmacokinetic half-life has been published for Bonothyrk. Like other short Khavinson peptides, its di-, tri- and tetrapeptide fractions are rapidly broken down by plasma and tissue peptidases, so the circulating half-life is expected to be on the order of minutes, and the oral bioavailability of intact peptide is likely low. The Khavinson model holds that the proposed benefit comes from a durable epigenetic change in gene expression rather than a sustained blood level, which is the stated rationale for short 30-day courses spaced 3-6 months apart.
How is Bonothyrk reconstituted and administered?expand_more
In real-world use Bonothyrk is not reconstituted at all; it is swallowed as 10 mg capsules with meals (a sublingual version also exists). For the educational subcutaneous model on this site, a 20 mg vial is mixed with 1.0 mL of bacteriostatic water to give 20 mg/mL: draw the water slowly down the vial wall, swirl gently until clear, and refrigerate. At that concentration one 10 mg capsule-equivalent measures 50 units (0.5 mL) on a U-100 insulin syringe. This is a measurement reference only; an oral supplement product is not formulated for injection.
Can Bonothyrk be stacked with other Khavinson peptide bioregulators?expand_more
In practice, Khavinson bioregulators are often used in sequence or in combination (for example pairing an organ-specific Cytomax like Bonothyrk with systemic peptides such as Epitalon), and the developer's materials describe multi-bioregulator regimens. However, there are no controlled studies validating any specific stack, and combining a parathyroid-targeted product with calcium, vitamin D, bisphosphonates, or PTH analogs has not been studied and could affect calcium balance unpredictably. Treat any combination as experimental and discuss it with a clinician, especially if you have bone or parathyroid conditions.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Bonothyrk, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VK, Anisimov VN. Peptide regulation of aging: 35-year research experience. Bull Exp Biol Med. 2009;148(1):94-98. View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. View Scientific Paper →
Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. View Scientific Paper →
Physiology, Parathyroid Hormone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated 2022. View Scientific Paper →
Physiology, Parathyroid. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. View Scientific Paper →
Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Communication 1. Results of experimental studies. Adv Gerontol. 2013;3(3):186-194 (PMID 23734519). View Scientific Paper →